Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17003454rdf:typepubmed:Citationlld:pubmed
pubmed-article:17003454lifeskim:mentionsumls-concept:C0242383lld:lifeskim
pubmed-article:17003454lifeskim:mentionsumls-concept:C0600518lld:lifeskim
pubmed-article:17003454lifeskim:mentionsumls-concept:C0796392lld:lifeskim
pubmed-article:17003454lifeskim:mentionsumls-concept:C0017921lld:lifeskim
pubmed-article:17003454lifeskim:mentionsumls-concept:C1314792lld:lifeskim
pubmed-article:17003454lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:17003454lifeskim:mentionsumls-concept:C1412379lld:lifeskim
pubmed-article:17003454lifeskim:mentionsumls-concept:C0205390lld:lifeskim
pubmed-article:17003454lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:17003454lifeskim:mentionsumls-concept:C1517572lld:lifeskim
pubmed-article:17003454lifeskim:mentionsumls-concept:C1656863lld:lifeskim
pubmed-article:17003454pubmed:issue10lld:pubmed
pubmed-article:17003454pubmed:dateCreated2006-9-27lld:pubmed
pubmed-article:17003454pubmed:abstractTextTo evaluate the safety of three dose regimens of intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA) for the management of choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).lld:pubmed
pubmed-article:17003454pubmed:languageenglld:pubmed
pubmed-article:17003454pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17003454pubmed:citationSubsetIMlld:pubmed
pubmed-article:17003454pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17003454pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17003454pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17003454pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17003454pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17003454pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17003454pubmed:statusMEDLINElld:pubmed
pubmed-article:17003454pubmed:monthOctlld:pubmed
pubmed-article:17003454pubmed:issn0146-0404lld:pubmed
pubmed-article:17003454pubmed:authorpubmed-author:ScottIngrid...lld:pubmed
pubmed-article:17003454pubmed:authorpubmed-author:JorgeRodrigoRlld:pubmed
pubmed-article:17003454pubmed:authorpubmed-author:CardilloJosé...lld:pubmed
pubmed-article:17003454pubmed:authorpubmed-author:CostaRogério...lld:pubmed
pubmed-article:17003454pubmed:authorpubmed-author:CalucciDaniel...lld:pubmed
pubmed-article:17003454pubmed:authorpubmed-author:MeloLuiz A...lld:pubmed
pubmed-article:17003454pubmed:issnTypePrintlld:pubmed
pubmed-article:17003454pubmed:volume47lld:pubmed
pubmed-article:17003454pubmed:ownerNLMlld:pubmed
pubmed-article:17003454pubmed:authorsCompleteYlld:pubmed
pubmed-article:17003454pubmed:pagination4569-78lld:pubmed
pubmed-article:17003454pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:meshHeadingpubmed-meshheading:17003454...lld:pubmed
pubmed-article:17003454pubmed:year2006lld:pubmed
pubmed-article:17003454pubmed:articleTitleIntravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.lld:pubmed
pubmed-article:17003454pubmed:affiliationU.D.A.T. Macular Imaging and Treatment Division, Hospital de Olhos de Araraquara, Araraquara, SP, Brazil. roger.retina@globo.comlld:pubmed
pubmed-article:17003454pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17003454pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:17003454pubmed:publicationTypeClinical Trial, Phase Illd:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17003454lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17003454lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17003454lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17003454lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17003454lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17003454lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17003454lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17003454lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17003454lld:pubmed